Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer
Authors: Eileen M. O'Reilly
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. July 17, 2023 Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. July 17, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00898 Journal of Clinical Oncology - published online before print July 17, 2023 PMID: 37459753 Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Eileen M. O'Reilly , MD1,2,3xEileen M. O'ReillySearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Memorial Sloan Kettering Cancer Center, New York, NY3Weill Cornell Medicine, New York, NY https://doi.org/10.1200/JCO.23.00898 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2007 and 2008, Giantonio et al1 and Saltz et al2 reported that the addition of bevacizumab combined with oxaliplatin-based therapy in metastatic colorectal cancer led to improvement in overall survival in second-line treatment and improvement in progression-free survival in first-line therapy, respectively. These studies established bevacizumab and cytotoxic therapy as a reference standard in this disease, upheld and widely used on a global basis to this day.SUPPORTCancer Center Support Grant/Core Grant No. P30 CA008748.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Eileen M. O'Reilly This author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, Autem Medical (I), Eisai (I), Exelixis (I), Genentech/Roche (I), Helio Health (I), Incyte (I), Ipsen, Merck, QED Therapeutics (I), Yiviva (I), Novartis, Boehringer IngelheimResearch Funding: AstraZeneca/MedImmune (Inst), Celgene (Inst), Genentech (Inst), Roche (Inst), Arcus Ventures (Inst), BioNTech (Inst), Bristol Myers Squibb (Inst), Helsinn Healthcare (Inst), Puma Biotechnology (Inst), QED Therapeutics (Inst), Yiviva (Inst)Uncompensated Relationships: Thetis PharmaNo other potential conflicts of interest were reported. Companion Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200